Peter is Chief Executive Officer and Chief Medical Officer at Third Arc Bio.

Prior to Third Arc Bio, Peter served as the Global Head of Oncology R&D for Johnson & Johnson (J&J) overseeing an end-to-end research and development organization that delivered 13 new drugs to market with over 60 approvals. Over his career, Peter has delivered multiple first and best-in-class transformational medicines and his innovative approach to drug development resulted in 12 FDA Breakthrough Therapy Designations and 38 New England Journal of Medicine publications for J&J medicines.

Prior to J&J, Peter also held multiple leadership roles at GlaxoSmithKline (GSK) including Vice President, Global Head of Oncology Early Clinical Development and Vice President and Medical Development Leader in Late Development. In these roles, he successfully filed 10 Investigational New Drug applications and played a leading role in taking two medicines from early discovery through global registration trials by setting a new benchmark with a “novel-novel” drug combination approach.

He also serves as a CEO partner at Omega Funds and as a board director at Neomorph.

Peter earned his MD and PhD in cell and molecular biology from the University of Pennsylvania and completed his training in internal medicine and oncology at Duke University and the National Cancer Institute.